Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
29 June 2022FormTreating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.
Part of a collection: Life Saving Drugs Program resources – Gaucher diseaseLife Saving Drugs Program – Gaucher disease (type 1) – Initial application
29 June 2022FormTreating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Gaucher diseaseLife Saving Drugs Program – Information for patients
29 June 2022Fact sheetHealth professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Coronavirus (COVID-19) at a glance – 20 June 2022
21 June 2022InfographicThis infographic provides a quick view of the coronavirus (COVID-19) situation in Australia on 20 June 2022
Part of a collection: Coronavirus (COVID-19) at a glance infographic collection- 17 June 2022Presentation
In celebration of Men’s Health Week, hear from Dr Lucas de Toca on how family history and lifestyle impact our health and learn tips to help maintain a healthy lifestyle.
- 17 June 2022Presentation
Hear from Dr Lucas de Toca talk about whether men are more susceptible to certain illnesses or conditions compared to women, and when men should start regular health checks and screening tests.
Part of a collection: We answer your top 3 questions National Bowel Cancer Screening Program – Do the bowel test poster
3 June 2022PosterThis poster reminds patients to do their bowel screening.
- 31 May 2022Presentation
Hear Doctor Lucas De Toca, COVID-19 Primary Care Response First Assistant Secretary, talk about chronic illness.
Part of a collection: We answer your top 3 questions Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 24 June 2022
27 May 2022AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 12th meeting on 24 June 2022
National Site of Recognition Steering Committee communique – 1 November 2021
25 May 2022Meeting minutesDetails of the meeting of the National Site of Recognition for thalidomide survivors and their families Steering Committee held on 1 November 2021.
Part of a collection: National Site of Recognition Steering Committee – CommuniquesNational Site of Recognition Steering Committee communique – 9 December 2021
25 May 2022Meeting minutesDetails of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.
Part of a collection: National Site of Recognition Steering Committee – CommuniquesNational Site of Recognition Steering Committee communique – 20 January 2022
25 May 2022Meeting minutesThis communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.
Part of a collection: National Site of Recognition Steering Committee – CommuniquesLife Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
13 May 2022ReportThis document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
- 15 March 2022Presentation
Professor Michael Kidd, Deputy Chief Medical Officer, discusses making healthy choices, and the small steps we can take every day to enjoy a healthy life.
Part of a collection: We answer your top 3 questions Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
21 January 2022AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
HCAF support categories fact sheet
5 January 2022Fact sheetThis fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesThalidomide health practitioner evidence form
4 January 2022Fact sheetThis form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the HCAF fact sheet
4 January 2022Fact sheetThis factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesEAF support categories fact sheet
4 January 2022Fact sheetThis fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the EAF fact sheet
4 January 2022Fact sheetThis fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesTackling Indigenous Smoking program – Mid-term evaluation report – Executive summary – May 2021
15 December 2021ReportThis executive summary of the TIS mid term evaluation report, completed in May 2021, summarises the interim findings from the independent evaluation of the TIS program 2018–19 to 2021–22.
Tackling Indigenous Smoking program – Mid-term evaluation report – December 2020
15 December 2021ReportThis mid-term evaluation report, completed in December 2020, presents the interim findings from the independent evaluation of the short and medium-term outcome objectives for the TIS program 2018–19 to 2021–22.
Tackling Indigenous Smoking program – Final evaluation report – July 2018
15 December 2021ReportThis report, completed in July 2018, evaluates how effective the Tackling Indigenous Smoking (TIS) program has been and whether it’s on target to achieve its long-term goals.
National Cancer Screening Register – addendum to privacy impact assessment
9 December 2021ReportThis report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Reapplication
8 December 2021FormTreating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)
29 June 2022 – Coronavirus (COVID-19) health alert
29 June 2022 – Japanese encephalitis virus (JEV) health alert
29 June 2022 – Monkeypox (MPX) health alert